Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. - sprookjes - yvandenbroek - TriplyDB

Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis.

Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis.

http://www.wikidata.org/entity/Q30413773

about

Update in Cystic Fibrosis 2014 Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis Oral anti-pseudomonal antibiotics for cystic fibrosis Oral anti-pseudomonal antibiotics for cystic fibrosis Inhaled anti-infective chemotherapy for respiratory tract infections: successes, challenges and the road ahead Clinical applications of pulmonary delivery of antibiotics Fluoroquinolones in the treatment of bronchopulmonary disease in cystic fibrosis Standard care versus protocol based therapy for new onset Pseudomonas aeruginosa in cystic fibrosis Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis Inhaled antibiotics for lower airway infections.Pseudomonas aeruginosa infection in patients with cystic fibrosis: scientific evidence regarding clinical impact, diagnosis, and treatment Recent advances in the treatment of Pseudomonas aeruginosa infections in cystic fibrosis Pseudomonas aeruginosa phenotypes associated with eradication failure in children with cystic fibrosis.Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial.State of progress in treating cystic fibrosis respiratory disease.Conditions associated with the cystic fibrosis defect promote chronic Pseudomonas aeruginosa infection Pseudomonas aeruginosa in cystic fibrosis patients with G551D-CFTR treated with ivacaftor.Future directions in early cystic fibrosis lung disease research: an NHLBI workshop report Risk of hemoptysis in cystic fibrosis clinical trials: A retrospective cohort study Tackling the increasing complexity of CF care.Change in Pseudomonas aeruginosa prevalence in cystic fibrosis adults over time.Impact of Sustained Eradication of New Pseudomonas aeruginosa Infection on Long-term Outcomes in Cystic Fibrosis.Risk factors for age at initial Pseudomonas acquisition in the cystic fibrosis epic observational cohort.Children and young adults with CF in the USA have better lung function compared with the UK.Pseudomonas aeruginosa serology and risk for re-isolation in the EPIC trial Effects of azithromycin in Pseudomonas aeruginosa burn wound infection.Antibiotic and anti-inflammatory therapies for cystic fibrosis.Progress in cystic fibrosis and the CF Therapeutics Development Network Incidence and clinical significance of elevated liver function tests in cystic fibrosis clinical trials.Risk factors for the progression of cystic fibrosis lung disease throughout childhood.Update in cystic fibrosis 2011.Current dilemmas in antimicrobial therapy in cystic fibrosis.Inhaled ciprofloxacin for chronic airways infections caused by Pseudomonas aeruginosa.Aerosolized antibiotics in cystic fibrosis: an update.Use of inhaled tobramycin in cystic fibrosis.Long-term safety and efficacy of tobramycin in the management of cystic fibrosis.Improving complex medical care while awaiting next-generation CFTR potentiators and correctors: The current pipeline of therapeutics.Management of Pseudomonas aeruginosa infection in cystic fibrosis patients using inhaled antibiotics with a focus on nebulized liposomal amikacin Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis.Understanding persistent bacterial lung infections: clinical implications informed by the biology of the microbiota and biofilms

P2860

Q22306307-BF083998-E186-49C2-8C59-CB9F22C3CBA8 Q24188054-199EA40B-3FC9-4939-8C58-7E5FD6C732C6 Q24202879-7CC1AAD7-7BDF-4D5F-BA8A-25B0F37E102A Q26471106-8AA15CF5-930A-49B6-8390-370A74F27A63 Q26822988-85FADC5A-6E30-4FAF-B06A-3C76FB3561FD Q26996053-5326377D-F9D9-4F35-A77A-6216075BD9A2 Q27004711-599F7FA6-E69E-4C97-88A8-83D06C43FC2F Q30412485-921B58CA-3F74-4AD4-B551-02BF795DA738 Q30422695-FCA31E96-4BA6-468B-A9A2-FAE18E657517 Q33640488-24920DCC-216E-4A8A-BDC7-F84D3156FA1C Q33824149-82A01F70-C33B-495B-84B4-2C15AEE9D213 Q33862073-822B71B9-F931-4BA1-961E-81B52F518CCE Q34106186-A625B869-1A94-4C59-A18E-85BD9E93AF64 Q34275485-B2F3D61F-9BEF-4A1D-AFCD-AE47EE1665CD Q34375926-F8436764-F16A-4037-8536-55BD3393FAC9 Q34479389-3A2ACB9C-1CF5-4B61-AF0E-6D6F9ADD2199 Q35127240-449057CF-646F-4F44-8368-68752EA74C3F Q35988949-9FF1685C-E33F-494A-AB42-5BE151E8E390 Q35995606-C4940CF7-C714-4252-AF13-1EAC4F091321 Q36034488-D7A1B266-B37B-4EE6-B164-6E4ADD9026D4 Q36215326-20DA14BC-22C7-4071-B9BF-7F06CF13FC3D Q36226940-3BE10382-5D52-4878-81FB-CAF67C68FC83 Q36673569-6497720F-C792-421D-97DF-905229D8EB3D Q36818364-6107F058-1EFA-4ED3-A2D5-A49299BD4BC5 Q36966187-B988810D-F66C-423F-9730-88CB927C221F Q37018035-96DE6000-2FE2-4077-9C6F-651738FACBD7 Q37201467-F99A5E7C-DACD-4474-BC80-3A63F8141EAD Q37209004-E802DAD0-0C69-483A-9412-2A320410AF69 Q37628124-0DF2C19C-4559-4C07-A6C1-B2210CA68D74 Q37679783-1FB7C565-8205-4BC9-A8E1-98FC10A51D4D Q38006922-E2E7B4D8-4B7C-44BB-B471-BC92EE4EADAC Q38042719-0A0C27BA-41A9-472B-B894-1F91876408EB Q38068608-EAC68670-C606-4524-892E-F8409DFB6396 Q38212537-59DAF438-6F0E-44DF-A6CC-C056DA10FD39 Q38332222-09F1C79C-0B0B-485D-907F-BB04EFF7FF51 Q38384994-ABDF6592-CC07-4000-BC93-C0161AB38392 Q38579967-017E6B47-C7A1-43EE-90E9-A9667C8E080F Q38634682-EC3D0B9D-7A10-468D-A161-9124E4C09848 Q38821019-70437106-4ADA-4C22-BBA2-1F908AEB5F35 Q39167799-1ED257A2-9DF0-47F1-8F6F-8C33954139F5

P2860

Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis.

http://www.wikidata.org/entity/Q30413773

description

2011 nî lūn-bûn

@nan

2011 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Comparative efficacy and safet ...... children with cystic fibrosis.

@ast

Comparative efficacy and safet ...... children with cystic fibrosis.

@en

type

label

Comparative efficacy and safet ...... children with cystic fibrosis.

@ast

Comparative efficacy and safet ...... children with cystic fibrosis.

@en

prefLabel

Comparative efficacy and safet ...... children with cystic fibrosis.

@ast

Comparative efficacy and safet ...... children with cystic fibrosis.

@en

P1433

Q30413773-1F6040B7-621D-4234-91A6-7ED56C7BF747

P1476

Q30413773-1D836349-4E1E-4C0C-8E68-F5599CF1B6B0

P2093

Q30413773-181AFC51-A7E6-4143-8565-EC6ED50A8C88

Q30413773-3F316592-63C8-447B-A795-181EE3D459C4

Q30413773-44FC2494-CAF9-4CAC-994D-3CD536ECB4E0

Q30413773-7C1C4CCA-7F1E-41A1-9B94-A0C67689648E

Q30413773-905D34DA-6945-4EB1-8D3E-764FE3D810D0

Q30413773-934771A3-10F2-4F14-83C5-751A864570B1

Q30413773-96BE967B-CBB9-4614-8896-473577B51D1C

Q30413773-9B3F02DC-AB63-48F9-9BED-F5EAE39AEB39

Q30413773-B2DF0C45-AFF5-4355-84D4-8D5E430949B9

Q30413773-C0AA384A-D4CE-4BDF-9A38-77834083943B

P2860

Q30413773-02341691-58C9-49EF-92B3-151B9A8B3D7B

Q30413773-03D09318-F960-457B-81B8-33FA88B73919

Q30413773-13BC134D-2F93-4873-8679-70699E69E0AE

Q30413773-186A1321-4E7B-4857-8A20-4C5B71D5AE37

Q30413773-21B76AD3-364D-4056-B908-391E55191562

Q30413773-457173E4-A34A-4B68-B77D-D81C31AFA9DB

Q30413773-4B309391-6190-4CFF-8402-8B616F0EE2F9

Q30413773-4D0CBBD8-8752-4ACC-82FE-F7D3E94D49C8

Q30413773-5D8464DC-4E8A-499D-8D38-0CD0D25F6B99

Q30413773-698F8BAB-6AE2-42E6-86E0-00E6206D2569

P304

Q30413773-5AE5FB13-C094-4DC9-85D5-E5439FF74AB2

P31

Q30413773-C08FB727-6B49-4B63-B953-0DFD2716B14F

P356

Q30413773-A3F352E6-DEB1-489B-8D83-9A3C96D72E9F

P407

Q30413773-2EB0ABD7-F3A5-427B-A313-5945BADC0098

P433

Q30413773-E3CAC1B9-B621-4164-9DBC-F5197DED6F2C

P478

Q30413773-C31ECAC8-A67C-49D9-B398-0A081F4486CD

P50

Q30413773-7464E7D4-8A8C-4630-86FE-FC561BC6E170

P577

Q30413773-08D7EB52-FA73-4224-BD1A-4D7EBDE898D3

P698

Q30413773-92C25139-792E-401B-AE83-4D8010B54432

P921

Q30413773-15A12334-5620-412D-82D3-26C704B8EFC2

Q30413773-9E019E77-1E31-4546-B11C-9805748F338F

P932

Q30413773-625E6230-831A-4D16-A995-A725DFCF29C4

P356

ARCHPEDIATRICS.2011.136

P1433

JAMA Pediatrics

P1476

Comparative efficacy and safet ...... children with cystic fibrosis

@en

P2093

Barbara A Chatfield

http://www.w3.org/2001/XMLSchema#string

Bonnie W Ramsey

http://www.w3.org/2001/XMLSchema#string

David Orenstein

http://www.w3.org/2001/XMLSchema#string

Deborah K Froh

http://www.w3.org/2001/XMLSchema#string

Early Pseudomonas Infection Control (EPIC) Investigators

http://www.w3.org/2001/XMLSchema#string

George Retsch-Bogart

http://www.w3.org/2001/XMLSchema#string

Jane L Burns

http://www.w3.org/2001/XMLSchema#string

Judy Williams

http://www.w3.org/2001/XMLSchema#string

Margaret Rosenfeld

http://www.w3.org/2001/XMLSchema#string

Miriam M Treggiari

http://www.w3.org/2001/XMLSchema#string

P2860

Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis

Bacterial biofilms: a common cause of persistent infections

The diagnosis of cystic fibrosis: a consensus statement. Cystic Fibrosis Foundation Consensus Panel

Quorum-sensing signals indicate that cystic fibrosis lungs are infected with bacterial biofilms

Early anti-pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study'

Pulmonary outcome in cystic fibrosis is influenced primarily by mucoid Pseudomonas aeruginosa infection and immune status and only modestly by genotype.

Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus.

Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group.

An official American Thoracic Society/European Respiratory Society statement: pulmonary function testing in preschool children.

Association between Stenotrophomonas maltophilia and lung function in cystic fibrosis.

P304

847-856

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1001/ARCHPEDIATRICS.2011.136

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

165

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21893650

http://www.w3.org/2001/XMLSchema#string

P921

cystic fibrosis

Pseudomonas aeruginosa

P932

3991697

http://www.w3.org/2001/XMLSchema#string